Registry for early Alzheimer-related memory problems
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study registry collects health and brain-testing information for people with mild cognitive impairment or early Alzheimer’s dementia. It may help researchers better understand early Alzheimer disease and plan future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been told you have mild cognitive impairment or early Alzheimer-related dementia, not moderate dementia
- Brain or memory test results show cognitive impairment but you haven’t progressed to a moderate stage
- Alzheimer confirmation test is positive (amyloid PET scan and/or spinal fluid test)
- You had a 3T brain MRI within the last 6 months
- You have a care partner who can help with study visits and information
- Your Alzheimer care is through an approved BI-Lahey amyloid clinic and your medications are stable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects information from people with mild cognitive impairment or Alzheimer's disease who are starting a new medication. It helps researchers learn more about these conditions and their treatments over time.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
This study creates a registry for people who are using newly approved Alzheimer's medications. It tracks how these treatments work over time and may help researchers learn more about diagnosing and treating Alzheimer's.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.